Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms

Experimental Hematology

Volumn 35, Issue 11, 2007, Pages 1668-1676

  Najfeld, Vesna ^a   Cozza, Amanda ^a   Berkofsy Fessler, Windy ^a   Prchal, Josef ^b   Scalise, Angela ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2;

ADULT; AGED; ARTICLE; CHROMOSOME 9P; CHROMOSOME ABERRATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN CELL; INTERPHASE; KARYOTYPE; LYMPHOMA; MALE; METAPHASE; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; TETRASOMY; TRISOMY;

ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; GENE DOSAGE; GENE REARRANGEMENT; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; JANUS KINASE 2; LEUKEMIA, B-CELL; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; MUTATION; MYELOPROLIFERATIVE DISORDERS; PHILADELPHIA CHROMOSOME; PROTEIN TRANSPORT; RETROSPECTIVE STUDIES;

EID: 35448985694     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2007.08.025     Document Type: Article

References (51)

1. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 6 (1951) 372-375
2. Rowley J.D. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 243 (1973) 290-293
3. Heisterkamp N., Stam K., Groffen J., et al. Structural organization of the bcr gene and its role in the Ph' translocation. Nature 315 (1985) 758
4. Berk P.D., Goldberg J.D., Donovan P.B., Fruchtman S.M., Berlin N.L., and Wasserman L.R. Therapeutic recommendations in polycythemia vera based on the Polycythemia Vera Study Group protocols. Semin Hematol 23 (1986) 132-143
5. Harrison C.N., Gale R.E., Machin S.J., and Linch D.C. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood 93 (1999) 417-424
6. Andrieux J., and Demory J.L. Karyotype and molecular cytogenetic studies in polycythemia vera. Curr Hematol Rep 4 (2005) 224-229
7. Reilly J.T. Cytogenetic and molecular genetic abnormalities in agnogenic myeloid metaplasia. Semin Oncol 32 (2005) 359-364
8. Bacher U., Haferlach T., Kern W., et al. Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information. Ann Hematol 84 (2005) 250-257
9. Najfeld V., Montella L., Scalise A., and Fruchtman S. Exploring polycythemia vera with fluorescence in situ hybridization: additional cryptic 9p is the most frequent abnormality detected. Br J Haematol 119 (2002) 558-566
10. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 (1997) 2079-2088
11. Chronic myeloproliferative disease (MPD). Atlas of Genetics and Cytogenetics in Oncology and Haematology. Available at: http://atlasgeneticsoncology.org/Anomalies/Anomliste.html#MPD. Accessed.
12. Grimwade D., Walker H., Oliver F., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 92 (1998) 2322-2322
13. James C., Ugo V., Le Couedic J.P., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434 (2005) 1144-1148
14. Levine R.L., Wadleigh M., Cools J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7 (2005) 387-397
15. Kralovics R., Passamonti F., Buser A.S., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352 (2005) 1779-1790
16. Campbell P.J., Scott L.M., Buck G., et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based study on JAK2 V617F mutation status: a prospective study. Lancet 356 (2005) 1945-1953
17. Jelinek J., Oki Y., Gharibyan V., et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 106 (2005) 3370-3373
18. Steensma D.P., Dewald G.W., Lasho T.L., et al. The JAK2V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood 106 (2005) 1207-1209
19. Levine R.L., Belisle C., Wadleigh M., et al. X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood 107 (2006) 4139-4141
20. Kralovics R., Guan Y., and Prchal J.T. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol 30 (2002) 229-236
21. Peeters P., Raynaud S.D., Cools J., et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 90 (1997) 2535-2540
22. Griesinger F., Hennig H., Hillmer F., et al. A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia. Genes Chromosomes Cancer 44 (2005) 329-333
23. Reiter A., Walz C., Watmore A., et al. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCMI to JAK2. Cancer Res 65 (2005) 2662-2667
24. Mercher T., Wernig G., Moore S.A., et al. JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model. Blood 108 (2006) 2770-2779
25. Ihle J.N., and Gilliland D.G. JAK2: normal function and role in hematopoietic disorders. Curr Opin Genet Dev 17 (2007) 8-14
26. Scott L.M., Tong W., Levine R.L., et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356 (2007) 459-468
27. Malinge S., Ben-Abdelali R., Settegrana C., et al. Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. Blood 109 (2007) 2202-2204
28. Vizmanos J.L., Ormazábal C., Larráyoz M.J., Cross N.C., and Calasanz M.J. JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report of 349 patients. Leukemia 20 (2006) 534-535
29. Campbell P.J., and Green A.R. The myeloproliferative disorders. N Engl J Med 355 (2006) 2452-2466
30. Najfeld V., Coyle T., and Berk P.D. Transformation of polycythemia vera to acute nonlymphocytic leukemia accompanied by t(1;3)(p36;q21) karyotype. Cancer Genet Cytogenet 33 (1988) 193-200
31. In: Shaffer L.G., and Tommerup N. (Eds). An International System for Human Cytogenetic Nomenclature (2005), S. Karger, Basel
32. Nussenzveig R.H., Swierczek S.I., Jelinek J., et al. Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol 35 (2007) 32-38
33. Lippert E., Boissinot M., Kralovics R., et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood 108 (2006) 1865-1867
34. Delhommeau F., Pisani D.F., Casadevall N., Constantinescu S., and Vainchenker W. Oncogenic mechanisms in myeloproliferative disorders. Cell Mol Life Sci 63 (2006) 2939-2953
35. Campbell P.J., Baxter E.J., Beer P.A., et al. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations and role in leukemic transformation. Blood 108 (2006) 3548-3555
36. Schnittger S., Bacher U., Kern W., Haferlach C., and Haferlach T. JAK2V617F as a progression marker in CMPD and as cooperative mutation in AML with trisomy 8 and t(8;21): a comparative study on 1103 CMPD and 269 AML cases. Leukemia 21 (2007) 1843-1845
37. Bentz M., Barth B.F., Brüderlein S., et al. Gain of chromosome arm 9p is characteristic of primary mediastinal B-cell lymphoma (MBL): comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line. Genes Chromosomes Cancer 30 (2001) 393-401
38. Joos S., Otaño-Joos M.I., Ziegler S., et al. Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. Blood 87 (1996) 1571-1578
39. Szpurka A., Tiu R., Murugesan G., et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood 108 (2006) 2173-2181
40. Goerttler P.S., Kreutz C., Donauer J., et al. Gene expression profiling in polycythaemia vera: overexpression of transcription factor NF-E2. Br J Haematol 129 (2005) 138-150
41. Kralovics R., Teo S.S., Buser A.S., et al. Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood 106 (2005) 3374-3376
42. Schwaller J., Frantsve J., Aster J., et al. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J 17 (1998) 5321-5333
43. Carron C., Cormier F., Janin A., et al. TEL-JAK2 transgenic mice develop T-cell leukemia. Blood 95 (2000) 3891-3899
44. Lacronique V., Boureux A., Monni R., et al. Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells. Blood 95 (2000) 2076-2083
45. Onnebo S.M., Condron M.M., McPhee D.O., Lieschke G.J., and Ward A.C. Hematopoietic perturbation in zebrafish expressing a tel-jak2a fusion. Exp Hematol 33 (2005) 182-188
46. Najfeld, V. Conventional and molecular cytogenetics of ph-negative chronic myeloproliferative disorders. In: Tefferi A, Silver R, eds. Myeloproliferative Disorders: Molecular Pathogenesis and Practice in the JAK2 Mutations Era. Abingdon, UK: Informa Healthcare; in press.
47. Atlas of Genetics and Cytogenetics in Oncology and Haematology. Available at: http://atlasgeneticsoncology.org/Genes/AML1.html. Accessed.
48. Wang Q., Stacy T., Binder M., et al. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci U S A 93 (1996) 3444-3449
49. Lacronique V., Boureux A., Valle V.D., et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278 (1997) 1309-1312
50. dos Santos N.R., and Ghysdael J. A transgenic mouse model for TEL-JAK2-induced B-cell lymphoma/leukemia. Leukemia 20 (2006) 182-185
51. Desta F., Christiansen D.H., Anderson M.K., and Pedersen-Bjergaard J. Activating mutations of JAK2V617F are uncommon in t-MDS and t-AML and are only observed in atypic cases. Leukemia 20 (2006) 547-548